P1/2, N=28, Recruiting, Ohio State University Comprehensive Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

P2, N=30, Enrolling by invitation, Chinese University of Hong Kong

P=N/A, N=14, Not yet recruiting, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

P2, N=90, Recruiting, Delcath Systems Inc. | Not yet recruiting --> Recruiting

P1/2, N=140, Not yet recruiting, Institute Of Oncology Ljubljana

CHK1i+LDHU is a promising therapy for chemotherapy-resistant HGSOC, combining direct cytotoxic effects with reprogramming the TIME to reduce immunosuppression and activate a CD8+ T cell-dependent anti-tumour response.

E2F1 knockdown decreased the expression of genes associated with cell cycle regulation, migration, invasion, and DNA repair, further sensitizing chemoresistant SCLC cells to cisplatin...In vivo xenograft models demonstrated that the combination significantly inhibited tumor growth without causing significant toxicity. Our findings reveal the molecular mechanisms of SCLC chemoresistance and suggest potential therapeutic strategies targeting the BMX-E2F1 axis to overcome this challenge.

Taken together, dacarbazine and the miR-204-5p mimic favor the dissemination of B16 melanoma cells in the lungs, which may support further metastatic development. Although miR-204-5p has been described as a tumor-suppressive microRNA in melanoma, the application of a synthetic mimic to overexpress it in distant organs promoted tumor cell dissemination.

Pharmacologic inhibition of NQO1 using skullcapflavone II restores apoptotic sensitivity and enhances cisplatin efficacy, resulting in significant tumor suppression with favorable tolerability in preclinical models...Validation across seven independent cohorts, demonstrates robust performance in identifying patients at risk of progression and BCG failure. These findings establish a biologically grounded framework for precision management of T1HG bladder cancer.

Importantly, inhibition of miR-181a-5p abrogated the Treg-promoting effect of CDDP-induced tumour-derived EVs, a finding further validated in vivo, where blockade of miR-181a-5p not only impaired Treg differentiation but also restored T-cell-mediated antitumour immunity and restrained tumour growth. Together, these findings uncover a previously unrecognised mechanism by which CDDP exacerbates immunosuppression via miR-181a-5p-enriched EVs and suggest that targeting this pathway could improve the therapeutic efficacy of combination immunotherapy in ovarian cancer.

PG-NE exhibited potent cytotoxic, pro-apoptotic, and antimigratory activities in vitro. Its physicochemical stability and biological activity support its potential use as a chemopreventive or adjunctive agent.

They are notable for exhibiting cytotoxicity against human cervical carcinoma (HeLa) and human lung epithelial adenocarcinoma (A549) cell lines with potency greater than cisplatin, demonstrating that they have the potential to be effective anticancer drugs...These complexes can also stop the proliferation of A549 cancer cells by causing cell cycle arrest at the S-phase. Their efficiency as promising drugs for targeted cancer treatment is highlighted in this study.